Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NEOVACC doggybone personalised cancer vaccine
- Development stage
- Unknown
- Lead developer
- University of Liverpool
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
NEOVACC doggybone personalised cancer vaccine (dbPCV) is a personalised therapeutic neoantigen DNA vaccine developed by the University of Liverpool in collaboration with Touchlight and myNEO Therapeutics. The vaccine utilizes Touchlight's proprietary 'doggybone DNA' (dbDNA) technology, which is a non-viral, enzymatically produced, closed-loop DNA structure. Each vaccine is custom-manufactured for the individual patient, encoding a unique set of tumor-specific neoantigens identified through genomic sequencing of the patient's own cancer. The goal is to stimulate the patient's immune system, specifically T-cells, to recognize and attack tumor cells expressing these mutant proteins. It is currently being evaluated in a Phase I clinical trial (NEOVACC) for patients with advanced non-small cell lung cancer (NSCLC) who have high PD-L1 expression but have not achieved complete tumor clearance on standard pembrolizumab therapy.
- Other names
- doggybone personalised cancer vaccineNEOVACC
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on NEOVACC doggybone personalised cancer vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NEOVACC doggybone personalised cancer vaccine.